Thousands of samples for pharmacogenetic tests have been analysed in our laboratory since its establishment. In this article we describe some of the most interesting cases of CYP poor metabolisers associated with adverse reactions to psychotropic drugs. Prevention of disease/illness, including Adverse Drug Reaction (ADR), is an aim of modern medicine. Scientific data supports the fact that evaluation of drug toxicology includes several factors, one of which is genetic variations in pharmacodynamics and pharmacokinetics of drug pathways. These variations are only a part of toxicity evaluation, however, even if it would help to prevent only a small percentage of patients from suffering adverse drug reactions, especially life threatening ADRs, pharmacogenetic testing should play a significant role in any modern psychopharmacologic practice. Medical practitioners should also consider the use of other medications or alternative dosing strategies for drugs in patients identified as altered metabolisers. This will promise not only better and safer treatments for patients, but also potentially lowering overall healthcare costs.
Gershenfeld, H.K.; Philibert, R.A.; Boehm, G.W. Looking forward in geriatric anxiety and depression: Implications of basic science for the future. Am. J. Geriatr. Psychiatry 2005, 13, 1027–1040.
[3]
Bryant, S.G.; Fisher, S.; Kluge, R.M. Long-term versus short-term amitriptyline side effects as measured by a postmarketing surveillance system. J. Clin. Psychopharmacol. 1987, 7, 78–82.
[4]
Biggs, J.T.; Riesenberg, R.A.; Ziegler, V.E. Overdosing the tricyclic overdose patient. Am. J. Psychiatry 1977, 134, 461–462.
Bertilsson, L.; Nordin, C.; Otani, K.; Resul, B.; Scheinin, M.; Siwers, B.; Sjoqvist, F. Disposition of single oral doses of e-10-hydroxynortriptyline in healthy subjects, with some observations on pharmacodynamic effects. Clin. Pharmacol. Ther. 1986, 40, 261–267, doi:10.1038/clpt.1986.173.
[7]
Dalen, P.; Dahl, M.L.; Bernal Ruiz, M.L.; Nordin, J.; Bertilsson, L. 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin. Pharmacol. Ther. 1998, 63, 444–452, doi:10.1016/S0009-9236(98)90040-6.
[8]
Morita, S.; Shimoda, K.; Someya, T.; Yoshimura, Y.; Kamijima, K.; Kato, N. Steady-state plasma levels of nortriptyline and its hydroxylated metabolites in japanese patients: Impact of CYP2D6 genotype on the hydroxylation of nortriptyline. J. Clin. Psychopharmacol. 2000, 20, 141–149, doi:10.1097/00004714-200004000-00005.
[9]
Steimer, W.; Zopf, K.; von Amelunxen, S.; Pfeiffer, H.; Bachofer, J.; Popp, J.; Messner, B.; Kissling, W.; Leucht, S. Amitriptyline or not, that is the question: Pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy. Clin. Chem. 2005, 51, 376–385, doi:10.1373/clinchem.2004.041327.
[10]
van der Kuy, P.H.; Hooymans, P.M. Nortriptyline intoxication induced by terbinafine. Br. Med. J. 1998, 316.
[11]
Yue, Q.Y.; Zhong, Z.H.; Tybring, G.; Dalen, P.; Dahl, M.L.; Bertilsson, L.; Sjoqvist, F. Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in chinese subjects of different CYP2D6 genotypes. Clin. Pharmacol. Ther. 1998, 64, 384–390, doi:10.1016/S0009-9236(98)90069-8.
[12]
Degner, D.; Grohmann, R.; Kropp, S.; Ruther, E.; Bender, S.; Engel, R.R.; Schmidt, L.G. Severe adverse drug reactions of antidepressants: Results of the german multicenter drug surveillance program amsp. Pharmacopsychiatry 2004, 37 Suppl. 1, S39–S45, doi:10.1055/s-2004-815509.
[13]
Bond, G.R.; Garro, A.C.; Gilbert, D.L. Dyskinesias associated with atomoxetine in combination with other psychoactive drugs. Clin. Toxicol. 2007, 45, 182–185, doi:10.1080/15563650600981178.
[14]
Bosse, G.M.; Spiller, H.A.; Collins, A.M. A fatal case of venlafaxine overdose. J. Med. Toxicol. 2008, 4, 18–20, doi:10.1007/BF03160945.
[15]
Caroselli, C.; Ricci, G. The venlafaxine "heart revenge:" A short report. Clin. Cardiol. 2010, 33, E46–E47, doi:10.1002/clc.20505.
[16]
Drent, M.; Singh, S.; Gorgels, A.P.; Hansell, D.M.; Bekers, O.; Nicholson, A.G.; van Suylen, R.J.; du Bois, R.M. Drug-induced pneumonitis and heart failure simultaneously associated with venlafaxine. Am. J. Respir. Crit. Care Med. 2003, 167, 958–961, doi:10.1164/rccm.200207-739CR.
[17]
Garcia-Cabeza, I.; Blas, M.M.; Epifanio, M.M.; Chavez, M.G. Cognitive deterioration after venlafaxine overdose. J. Emerg. Med. 2009, 40, e103–e106.
[18]
Hojer, J.; Hulting, J.; Salmonson, H. Fatal cardiotoxicity induced by venlafaxine overdosage. Clin. Toxicol. 2008, 46, 336–337, doi:10.1080/15563650701358755.
[19]
Pan, J.J.; Shen, W.W. Serotonin syndrome induced by low-dose venlafaxine. Ann. Pharmacother. 2003, 37, 209–211.
[20]
Presecki, P.; Grosic, V.; Silic, A.; Mihanovic, M. Infection or idiosyncratic reaction to antiepileptic drugs? Psychiatr. Danub. 2010, 22, 132–134.
[21]
Thundiyil, J.G.; Kearney, T.E.; Olson, K.R. Evolving epidemiology of drug-induced seizures reported to a poison control center system. J. Med. Toxicol. 2007, 3, 15–19, doi:10.1007/BF03161033.
[22]
Vieweg, W.V.; Pandurangi, A.K.; Anum, E.A.; Lanier, J.O.; Fierro, M.F.; Fernandez, A. Toxicology findings in child and adolescent suicides in virginia: 1987–2003. Prim. Care Companion J. Clin. Psychiatry 2006, 8, 142–146, doi:10.4088/PCC.v08n0303.
[23]
Chan, A.N.; Gunja, N.; Ryan, C.J. A comparison of venlafaxine and ssris in deliberate self-poisoning. J. Med. Toxicol. 2010, 6, 116–121, doi:10.1007/s13181-010-0013-x.
[24]
de Leon, J.; Armstrong, S.C.; Cozza, K.L. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics 2006, 47, 75–85, doi:10.1176/appi.psy.47.1.75.
[25]
McAlpine, D.E.; O'Kane, D.J.; Black, J.L.; Mrazek, D.A. Cytochrome P450 2D6 genotype variation and venlafaxine dosage. Mayo Clin. Proc. 2007, 82, 1065–1068, doi:10.4065/82.9.1065.
[26]
Pilgrim, J.L.; Gerostamoulos, D.; Drummer, O.H. Review: Pharmacogenetic aspects of the effect of cytochrome P450 polymorphisms on serotonergic drug metabolism, response, interactions, and adverse effects. Forensic Sci. Med. Pathol. 2011, 7, 162–184, doi:10.1007/s12024-010-9188-3.
[27]
Seo, D.; Patrick, C.J.; Kennealy, P.J. Role of serotonin and dopamine system interactions in the neurobiology of impulsive aggression and its comorbidity with other clinical disorders. Aggress. Violent Behav. 2008, 13, 383–395, doi:10.1016/j.avb.2008.06.003.
[28]
Stingl, J.C.; Viviani, R. CYP2D6 in the brain: Impact on suicidality. Clin. Pharmacol. Ther. 2011, 89, 352–353, doi:10.1038/clpt.2010.239.
[29]
Yu, A.M.; Idle, J.R.; Byrd, L.G.; Krausz, K.W.; Kupfer, A.; Gonzalez, F.J. Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics 2003, 13, 173–181, doi:10.1097/00008571-200303000-00007.
[30]
Pitkov, I.; Jones, T.; van Vuuren, R. Suicide cases and venlafaxine. Acta Neuropsychiatr. 2011, 23, 156–160, doi:10.1111/j.1601-5215.2011.00566.x.
[31]
Piatkov, I.; Jones, T.; Rochester, C. Cytochrome P450 loss-of-function polymorphism genotyping on the agilent bioanalyzer and clinical application. Pharmacogenomics 2009, 10, 1987–1994, doi:10.2217/pgs.09.127.
[32]
Mihaljevic-Peles, A.; Sagud, M.; Bozina, N.; Zivkovic, M.; Jovanovic, N. Pharmacogenetics and antipsychotics in the light of personalized pharmacotherapy. Psychiatr. Danub. 2010, 22, 335–337.
[33]
Binder, E.B.; Holsboer, F. Pharmacogenomics and antidepressant drugs. Ann. Med. 2006, 38, 82–94, doi:10.1080/07853890600551045.
[34]
Wall, C.A.; Oldenkamp, C.; Swintak, C. Safety and efficacy pharmacogenomics in pediatric psychopharmacology. Prim. Psychiatry 2010, 17, 53–58.
[35]
Goldsmith, L.; Moncrieff, J. The psychoactive effects of antidepressants and their association with suicidality. Curr. Drug Saf. 2011, 6, 115–121.
[36]
Lucire, Y.; Crotty, C. Antidepressant-induced akathisia-related homicides associated with diminishing mutations in metabolizing genes of the CYP450 family. Pharmacogenomics Pers. Med. 2011, 4, 65–81, doi:10.2147/PGPM.S17445.
[37]
Musshoff, F.; Stamer, U.M.; Madea, B. Pharmacogenetics and forensic toxicology. Forensic Sci. Int. 2010, 203, 53–62, doi:10.1016/j.forsciint.2010.07.011.
[38]
Chaudhry, I.; Neelam, K.; Duddu, V.; Husain, N. Ethnicity and psychopharmacology. J. Psychopharmacol. 2008, 22, 673–680, doi:10.1177/0269881107082105.
[39]
Shimoda, K.; Noguchi, T.; Morita, S.; Ozeki, Y.; Shibasaki, M.; Someya, T.; Takahashi, S. Interindividual variations of desmethylation and hydroxylation of amitriptyline in a Japanese psychiatric population. J. Clin. Psychopharmacol. 1995, 15, 175–181, doi:10.1097/00004714-199506000-00005.
[40]
Amitai, Y.; Kennedy, E.; DeSandre, P.; Fawcett, J.; Frischer, H. Red cell and plasma concentrations of fluoxetine and norfluoxetine. Vet. Hum. Toxicol. 1993, 35, 134–136.
